Starpharma Anno IPO
Cos'è Anno IPO di Starpharma?
Anno IPO di Starpharma Holdings Limited è 2000
Qual è la definizione di Anno IPO?
L'offerta pubblica iniziale è un tipo di offerta pubblica in cui le azioni di una società di solito sono vendute a investitori istituzionali che, a loro volta, vendono al pubblico in generale, su una borsa valori, per la prima volta.
Through IPO a privately held company transforms into a public company. Initial public offerings are mostly used by companies to raise the expansion of capital, possibly to monetize the investments of early private investors, and to become publicly traded enterprises. A company selling shares is never required to repay the capital to its public investors. After the IPO, when shares trade freely in the open market, money passes between public investors.
Although IPO offers many advantages, there are also significant disadvantages, chief among these are the costs associated with the process and the requirement to disclose certain information that could prove helpful to competitors.
The IPO process is colloquially known as going public. Details of the proposed offering are disclosed to potential purchasers in the form of a lengthy document known as a prospectus. Most companies undertake an IPO with the assistance of an investment banking firm acting in the capacity of an underwriter. Underwriters provide several services, including help with correctly assessing the value of shares.
Anno IPO di aziende nel Health Care settore su ASX rispetto a Starpharma
Cosa fa Starpharma?
Starpharma Holdings Limited, a biopharmaceutical company, engages in the research, development, and commercialization of dendrimer products for pharmaceutical, life-science, and other applications worldwide. The company offers VivaGel, a non-antibiotic therapy for the management and prevention of bacterial vaginosis. It also develops VivaGel condom, an antiviral condom; and VIRALEZE, an antiviral nasal spray. In addition, the company develops DEP, a dendrimer drug delivery technology, including DEP docetaxel that is in Phase II clinical trials, DEP cabazitaxel that is in Phase II clinical trial, and DEP irinotecan that is in phase II clinical trials for the treatment of cancer; oncology programs, such as DEP radiopharmaceuticals, DEP HER-2 ADC, and DEP gemcitabine; DEP non-oncology candidates; and DEP AZD0466, which is in Phase I/II clinical trials to treat haematological tumours. The company was founded in 1996 and is headquartered in Abbotsford, Australia.
Aziende con anno ipo simili a Starpharma
- Arq ha Anno IPO di 1999
- TasFoods ha Anno IPO di 1999
- hopTo ha Anno IPO di 1999
- aap Implantate AG ha Anno IPO di 1999
- Invigor ha Anno IPO di 1999
- Encavis AG ha Anno IPO di 1999
- Starpharma ha Anno IPO di 2000
- SSR Mining Inc ha Anno IPO di 2001
- Bread Inc ha Anno IPO di 2001
- Exact Sciences ha Anno IPO di 2001
- Cross Country Healthcares ha Anno IPO di 2001
- Friedman Industries ha Anno IPO di 2001
- Chevron ha Anno IPO di 2001